A phase 1/2 study of nuvisertib (TP-3654), an investigational selective PIM1 kinase inhibitor, in combination with JAK inhibitors ruxolitinib or momelotinib in patients with myelofibrosis Meeting Abstract
| Authors: | Mascarenhas, J. O.; Rampal, R.; El Chaer, F.; Gupta, V.; Shimoda, K.; Kiladjian, J. J.; Passamonti, F.; Bose, P.; Scandura, J. M.; Mesa, R.; Rein, L. A. M.; Yuda, J.; Ross, D. M.; Devos, T.; Talpaz, M.; Hoffman, R.; Kabir, S.; Li, Z.; Foulks, J. M.; Ansaldo, K.; Seki, M.; Peddagali, V.; Shah, J. T.; Harrison, C. |
| Abstract Title: | A phase 1/2 study of nuvisertib (TP-3654), an investigational selective PIM1 kinase inhibitor, in combination with JAK inhibitors ruxolitinib or momelotinib in patients with myelofibrosis |
| Meeting Title: | 66th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 144 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Dec 7-10 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2024-11-05 |
| Start Page: | 6629 |
| End Page: | 6631 |
| Language: | English |
| ACCESSION: | WOS:001412545100026 |
| DOI: | 10.1182/blood-2024-200268 |
| PROVIDER: | wos |
| Notes: | Source: Wos |
